2025. Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: ​ Data From 11 Trials With Over 3000 Patient-Years of Exposure. SKIN The Journal of Cutaneous Medicine. 9, 1 (Jan. 2025), s511. DOI:https://doi.org/10.25251/skin.9.supp.511.